Companies / RAD

RADIOPHARM THERANOSTICS LIMITED

ASX:RADPharmaceuticals, Biotechnology & Life Sciences
4.71B shares on issueASX (delayed) · snapshot 28 Oct 20267.49B fully diluted+59.1% if every option and right converts$0.0045price · delayed$18.8MMarket capAt the previous close. On a day the price moves, shares × today’s price will differ. Prices delayed.

Today’s holders own 62.9% of what they think they own, once every option and right converts.

Very high
Dilution risk

Runway under 2 quarters; share count grew 115% in 24 months; 3 cash raises in 24 months

MinimalVery high
Absolute levels — not a ranking against other companies.
Cash runway0.9 quarters of funding
Share-count growth (24m)115.0%measured to the latest Appendix 2A, not to the share count above
Raise cadence (24m)3 cash raises
Options & rights overhang59.1% of shares
In-the-money supplyno data — an exercise price is on record for a minority of the supply
Pending proposed issuesopen proposed issue (Appendix 3B)

RADIOPHARM THERANOSTICS LIMITED's share-count change over the period is not available because its filed Appendix 2A series ends before the latest date. The company made three capital raises in the past 24 months, totalling A$58.9M, most recently a Placement (with concurrent US Direct Registration Offering) + Share Purchase Plan raising A$15.5M in July 2026. Options and rights could convert into 2.78B new shares, representing 59.1% of the current share count; none are in the money, and the nearest expiry is November 2026. The company has under 2 quarters of funding at the recent spend rate. One proposed securities issue (Appendix 3B) is pending with an expected date of December 2027.

AI-generated summary of this page's cited filings · updated 20 Oct 2026
Quick answers · 4

Is RAD raising capital?

Radiopharm Theranostics has 1 proposed issue of securities pending under Appendix 3B as at 28 Oct 2026; the most recent raise announced is Placement (with concurrent US Direct Registration Offering) + Share Purchase Plan of $15.5M on 24 July 2026.

How much placement capacity does RAD have left?

About 91% of the 15% placement capacity left, about 9% used in 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.

How much cash does RAD have?

In its quarterly cash report for the quarter ended 30 June 2026, Radiopharm Theranostics reported $4.1M of cash and estimated 0.3 quarters of funding available at its current rate of spending. That is the company's own estimate.

When do RAD's options expire?

Unexercised options and rights equal 59.1% of Radiopharm Theranostics's shares on issue; the nearest expiry is Nov 2026.

Get told when this changes
Get RAD alerts
Free for up to 2 companies. A daily email when RAD raises money, files a new share issue, drops below 2 quarters of cash or moves risk level.
59.1%
Options & rights overhang
—
In the moneyAn option whose exercise price is below the last closing share price, so converting it pays. These are the options most likely to become new shares soon. supply · most strikes not on record
1
Raises · last 12 months
0.9 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 4.71B per ASX (delayed) (snapshot 28 Oct 2026).
2B3B4BDec 24Nov 25Oct 26Cash raise · 24 July 2026Cash raise · 20 Oct 2025Cash raise · 10 Jan 20254.71B

Cash runway

0.9 qtrs OURS
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
Funds operations to about Jan 2027 at the reported spend rate.
Adds the $15.5M raise announced 24 July 2026 (filing).
FILED 0.3 qtrs · $4.1M cash · quarter ended 30 June 2026 · before the raise above came in
OURS our estimate, carried to todayOURSOur estimate for today. We take the cash in the company’s latest cash report, deduct spending since at its reported rate, and, for quarterly filers, add raises announced after it. It moves daily; announced money may not all be received yet.$4.1M cash at 30 Jun 2026 + $15.5M announced raises + $5.9M post-quarter items in the report + $8.0M grant or R&D refund due − $20.1M spent ($15.1M a quarter × 120 days) = $13.4M left → 0.9 qtrsFILED as the company reportedFILEDAs the company stated it in its latest cash report. Dated to the end of that period, it does not change until the next report.
Free account
14 cash reports on record — Cash runway history
Cash, net spend and cover trend from every Appendix 4C/5B and 4D/4E on record up to 30 June 2026.
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Issuance timeline

Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityOn issue, per this filingSource
20 Oct 20263H · cancellationRAD : ORDINARY FULLY PAID4.71BAppendix 3H
20 Oct 20263G · unquotedRAD : ORDINARY FULLY PAID4.71BAppendix 3G
1 Oct 20263H · cancellationRAD : ORDINARY FULLY PAID4.71BAppendix 3H
17 Sept 20262A · quoted issueRAD : ORDINARY FULLY PAID4.67BAppendix 2A
17 Sept 20262A · quoted issueRAD : ORDINARY FULLY PAID4.38BAppendix 2A
Free account
48 filings on record — Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Securities on issue over time

Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.

Free account
Securities on issue, by class
How the share count and each option and rights class moved, month by month, with every number in a table.
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Capital raises

3 cash raises in the last 24 months · 1 in the last 12 months

every 9.2 monthsaverage gap between raises
3.2 monthssince the most recent
10 Jan 2025 – 24 July 2026first to most recent in this window
$15.5M
Placement (with concurrent US Direct Registration Offering) + Share Purchase Plan
At 1.5c, 21.1% below the last close
24 July 2026 COMPLETE
Free account
5 raises on record — Full raise history
Issue price, shares issued, brokers and stated purpose for every raise on record.
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account
12 dated events on record — Forward supply calendar
Option expiries and proposed issues on one forward timeline, with the securities each could add.
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.

About 91% of the 15% placement capacity left — about 9% used by Appendix 3B filings in the last 12 months (estimate, as at 2026-10-28). One filing in the window states more under 7.1 than the whole allowance and is not counted, so usage may be higher than this. Holders passed a ratification we could not match to exactly one filing, or whose number of shares the result does not state, and shares issued with holder approval are not added to the base, so the true headroom may be higher.
Free account
Placement capacity — LR 7.1 / 7.1A
The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
1 pending issue on record — Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Unlocks on a paid plan
See plans

Options & convertible securities

59.1%
Options & rights overhang · of current shares
—
In-the-money supply · most strikes not on record
2.78B
Potential new shares
Nov 2026
Nearest expiry
What a price move would switch on
1.39B2.78B$0.004 now0.25× today ($0.001) — 0 of the priced supply in the money, 0.0% of shares on issue0.5× today ($0.002) — 0 of the priced supply in the money, 0.0% of shares on issue0.75× today ($0.003) — 0 of the priced supply in the money, 0.0% of shares on issue1× today ($0.004) — 0 of the priced supply in the money, 0.0% of shares on issue1.25× today ($0.006) — 0 of the priced supply in the money, 0.0% of shares on issue1.5× today ($0.007) — 0 of the priced supply in the money, 0.0% of shares on issue2× today ($0.009) — 0 of the priced supply in the money, 0.0% of shares on issue3× today ($0.013) — 0 of the priced supply in the money, 0.0% of shares on issue5× today ($0.022) — 0 of the priced supply in the money, 0.0% of shares on issue10× today ($0.045) — 0 of the priced supply in the money, 0.0% of shares on issue0.25×0.5×0.75×now1.25×1.5×2×3×5×10×

An exercise price is on record for only 1.1% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.004 today. No price up to ten times today’s switches on any more priced supply.

  • Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
  • 2.75B (98.9% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
  • 30.2M more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
CodeSecurityTypeExercise priceExpiryOn issueSource
RADAFOptionsPrice-triggered, no exercise price stated—25 Nov 20268.7MFiling
RADAGOptionsPrice-triggered$0.6025 Nov 20265.1MFiling
RADOOptionsPrice-triggered, no exercise price stated—30 Nov 202679.4MFiling
RADAIOptionsPrice-triggered$0.6027 May 2027740kFiling
RADAKOptionsPrice-triggered$0.601 June 20271.7MFiling
RADAJOptionsPrice-triggered$0.171 July 202712.4MFiling
RADOBOptionsPrice-triggered, no exercise price stated—31 Oct 20271.18BFiling
RADAPOptionsPrice-triggered$0.09024 Apr 20289.0MFiling
RADOCOptionsPrice-triggered, no exercise price stated—31 July 2029982.2MFiling
RADAABWarrantsPrice-triggered$3.7931 July 20291.3MFiling
RADAACWarrantsPrice-triggered$3.9531 July 202964kFiling
RADANOptionsPrice-triggered, no exercise price stated——503.2MFiling

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.

Free account
12 option lines on record — In-the-money value & price ladder
What each line is worth in the money today, the price ladder to the next tranche that converts, and the filing description behind every code.
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Director dealings

DateDirectorTypeSharesOptionsOtherValueSource
16 Oct 2026Bruce GoodwinSell—111k——3Y notice
16 Oct 2026Ian TurnerSell—111k——3Y notice
16 Oct 2026Paul HopperSell—111k——3Y notice
16 Oct 2026Riccardo CanevariSell—1.6M——3Y notice
Free account
21 notices on record — Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Free account: 2 full company unlocks every month, no card.
Unlock RAD freeSee plans

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Free account: 2 full company unlocks every month, no card.
Create free account

Latest announcements

27 Oct 2026Notice of Annual General Meeting/Proxy Form
26 Oct 2026$PRadiopharm receives $8M advance on FY26 R&D tax incentive
20 Oct 2026Notification regarding unquoted securities - RAD
20 Oct 2026Change of Director's Interest Notices x 4
20 Oct 2026Notification of cessation of securities - RAD
12 Oct 2026Non-Compliance with Listing Rule 10.11
5 Oct 2026RAD Completes Meeting with US FDA for Development of RAD101
1 Oct 2026Notification of cessation of securities - RAD
1 Oct 2026Change of Director's Interest Notice (RC)
30 Sept 2026Appendix 4G and Corporate Governance Statement
30 Sept 2026Annual Report and Form 20-F
22 Sept 2026Change of Director's Interest Notices x 4
17 Sept 2026Notification regarding unquoted securities - RAD
17 Sept 2026RADOC New Class Options Range of Units and Top 20 Holders
17 Sept 2026Application for quotation of securities - RAD
17 Sept 2026Application for quotation of securities - RAD
17 Sept 2026Share purchase plan completed
14 Sept 2026RAD oral presentation at SNO26 on RAD101 Phase IIb data
11 Sept 2026Results of Meeting
9 Sept 2026RAD Announces Positive Data from RAD301 P1 Imaging Trial

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.